Total Payments
$129,700
2024 Payments
$1,512
Companies
9
Transactions
108
Medicare Patients
1,352
Medicare Billing
$288,295
Payment Breakdown by Category
Consulting$74,307 (57.3%)
Other$36,720 (28.3%)
Research$8,626 (6.7%)
Travel$7,879 (6.1%)
Food & Beverage$2,168 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $74,307 | 32 | 57.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,720 | 13 | 28.3% |
| Unspecified | $8,626 | 7 | 6.7% |
| Travel and Lodging | $7,879 | 22 | 6.1% |
| Food and Beverage | $2,168 | 34 | 1.7% |
Payments by Type
General
$121,074
101 transactions
Research
$8,626
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kite Pharma, Inc. | $90,154 | 64 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $13,243 | 11 | $0 (2024) |
| Celgene Corporation | $10,001 | 13 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $6,974 | 5 | $0 (2023) |
| Gilead Sciences, Inc. | $6,192 | 10 | $0 (2018) |
| Legend Biotech USA Inc. | $2,805 | 1 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $111.66 | 1 | $0 (2018) |
| Genmab U.S., Inc. | $111.11 | 1 | $0 (2024) |
| bluebird bio, Inc. | $108.89 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,512 | 4 | Novartis Pharmaceuticals Corporation ($1,292) |
| 2023 | $2,647 | 4 | E.R. Squibb & Sons, L.L.C. ($2,009) |
| 2022 | $17,603 | 8 | Kite Pharma, Inc. ($12,481) |
| 2021 | $29,377 | 12 | Kite Pharma, Inc. ($18,760) |
| 2020 | $13,369 | 12 | Kite Pharma, Inc. ($9,236) |
| 2019 | $35,466 | 33 | Kite Pharma, Inc. ($33,499) |
| 2018 | $26,908 | 33 | Kite Pharma, Inc. ($16,178) |
| 2017 | $2,819 | 2 | Novartis Pharmaceuticals Corporation ($2,819) |
All Payment Transactions
108 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/01/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | — | Cash or cash equivalent | $1,291.72 | Research |
| Study: CCTL019E2202 • Category: Oncology | ||||||
| 06/10/2024 | bluebird bio, Inc. | LYFGENIA (Drug) | Food and Beverage | In-kind items and services | $30.52 | General |
| Category: sickle-cell | ||||||
| 03/14/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $111.11 | General |
| Category: Oncology | ||||||
| 02/20/2024 | bluebird bio, Inc. | — | Food and Beverage | In-kind items and services | $78.37 | General |
| 08/11/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $827.50 | General |
| 06/02/2023 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | — | Cash or cash equivalent | $638.48 | Research |
| Study: CCTL019E2202 • Category: Oncology | ||||||
| 04/11/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $519.00 | General |
| 01/11/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $662.00 | General |
| 12/21/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $3,710.00 | General |
| Category: CELLT | ||||||
| 12/21/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $313.58 | General |
| Category: CELLT | ||||||
| 12/08/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $114.58 | General |
| Category: CELLT | ||||||
| 12/08/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: CELLT | ||||||
| 09/08/2022 | Legend Biotech USA Inc. | CARVYKTI (Biological) | Consulting Fee | Cash or cash equivalent | $2,805.00 | General |
| Category: Oncology | ||||||
| 04/04/2022 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: CELLT | ||||||
| 03/31/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $3,320.00 | General |
| Category: CELLT | ||||||
| 02/11/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,317.00 | General |
| 12/13/2021 | Novartis Pharmaceuticals Corporation | KYMRIAH (Biological) | — | In-kind items and services | $2,500.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH KYMRIAH RESEARCH • Category: ONCOLOGY | ||||||
| 11/23/2021 | Kite Pharma, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $3,560.00 | General |
| Category: CELLT | ||||||
| 11/23/2021 | Kite Pharma, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $1,980.00 | General |
| Category: CELLT | ||||||
| 10/27/2021 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,648.00 | General |
| 09/30/2021 | Kite Pharma, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $5,020.00 | General |
| Category: CELLT | ||||||
| 09/09/2021 | Kite Pharma, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $3,560.00 | General |
| Category: CELLT | ||||||
| 08/12/2021 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| 06/14/2021 | Novartis Pharmaceuticals Corporation | KYMRIAH (Biological) | Consulting Fee | Cash or cash equivalent | $3,125.00 | General |
| Category: ONCOLOGY | ||||||
| 06/09/2021 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: CELLT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,794 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH KYMRIAH RESEARCH | Novartis Pharmaceuticals Corporation | $2,500 | 1 |
| CCTL019E2202 | Novartis Pharmaceuticals Corporation | $1,930 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,402 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 394 | 1,025 | $248,847 | $97,739 |
| 2022 | 8 | 322 | 859 | $175,170 | $76,117 |
| 2021 | 7 | 317 | 744 | $154,343 | $61,465 |
| 2020 | 6 | 319 | 760 | $136,367 | $52,973 |
Total Patients
1,352
Total Services
3,388
Medicare Billing
$288,295
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 119 | 404 | $84,718 | $43,083 | 50.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 83 | 324 | $84,548 | $29,285 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 74 | 143 | $26,591 | $9,964 | 37.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 13 | 30 | $20,484 | $4,865 | 23.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 28 | 32 | $14,208 | $4,239 | 29.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 18 | 18 | $5,940 | $2,335 | 39.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 24 | $4,368 | $1,389 | 31.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 19 | 20 | $3,651 | $1,169 | 32.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 11 | 11 | $2,912 | $958.65 | 32.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 14 | 19 | $1,427 | $452.01 | 31.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 107 | 336 | $58,328 | $35,605 | 61.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 60 | 264 | $64,680 | $20,512 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 69 | 148 | $24,408 | $10,341 | 42.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 25 | 32 | $15,200 | $4,832 | 31.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $4,594 | $2,101 | 45.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 17 | 20 | $3,420 | $1,094 | 32.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 21 | $2,769 | $1,073 | 38.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 16 | 23 | $1,771 | $559.03 | 31.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 110 | 295 | $46,791 | $20,025 | 42.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 59 | 242 | $60,074 | $19,241 | 32.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 66 | 116 | $19,620 | $12,858 | 65.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 36 | 37 | $17,847 | $5,545 | 31.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $3,890 | $1,855 | 47.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 17 | 19 | $3,291 | $1,053 | 32.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 22 | $2,830 | $887.91 | 31.4% |
About Dr. Joseph Mcguirk, D.O
Dr. Joseph Mcguirk, D.O is a Hematology & Oncology healthcare provider based in Kansas City, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811969272.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Mcguirk, D.O has received a total of $129,700 in payments from pharmaceutical and medical device companies, with $1,512 received in 2024. These payments were reported across 108 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($74,307).
As a Medicare-enrolled provider, Mcguirk has provided services to 1,352 Medicare beneficiaries, totaling 3,388 services with total Medicare billing of $288,295. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Kansas City, KS
- Active Since 02/01/2006
- Last Updated 05/13/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1811969272
Products in Payments
- Yescarta (Drug) $85,126
- KYMRIAH (Biological) $11,313
- Tecartus (Drug) $9,000
- JCAR017 (Drug) $4,892
- CARVYKTI (Biological) $2,805
- KYMRIAH (Drug) $1,930
- Epkinly (Drug) $111.11
- LYFGENIA (Drug) $30.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Kansas City
Dr. Suman Kambhampati, Md, MD
Hematology & Oncology — Payments: $281,918
Hematology & Oncology $281,918
Dr. Shahzad Raza, Md, MD
Hematology & Oncology — Payments: $184,113
Hematology & Oncology $184,113
Dr. Stephanie Graff, M.d, M.D
Hematology & Oncology — Payments: $120,151
Hematology & Oncology $120,151
Jaswinder Singh, Md, MD
Hematology & Oncology — Payments: $86,702
Hematology & Oncology $86,702
Dr. Tara Lin, Md, MD
Hematology & Oncology — Payments: $24,114
Hematology & Oncology $24,114
Maureen Sheehan, M.d, M.D
Hematology & Oncology — Payments: $18,955
Hematology & Oncology $18,955